Stryker (NYSE: SYK) and HeartWare International (NASDAQ:HTWR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.
This table compares Stryker and HeartWare International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
74.5% of Stryker shares are owned by institutional investors. 7.4% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Stryker pays an annual dividend of $1.88 per share and has a dividend yield of 1.2%. HeartWare International does not pay a dividend. Stryker pays out 70.1% of its earnings in the form of a dividend. HeartWare International has increased its dividend for 7 consecutive years.
Valuation and Earnings
This table compares Stryker and HeartWare International’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Stryker||$12.44 billion||4.75||$1.02 billion||$2.68||58.91|
Stryker has higher revenue and earnings than HeartWare International. HeartWare International is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Stryker and HeartWare International, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stryker currently has a consensus target price of $162.32, indicating a potential upside of 2.81%.
Stryker beats HeartWare International on 10 of the 12 factors compared between the two stocks.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
HeartWare International Company Profile
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.